StockNow
Log in
Global Markets

AstraZeneca (AZN LN) guides FY26 GM to be stable to slightly higher than 2025; H2 margin should decline vs. H1 due to the seasonal mix of lower-margin FluMist and Beyfortus sales

StockNow breaking-news AI analysis

AstraZeneca expects stable FY26 gross margins versus 2025, but anticipates a seasonal H2 decline due to higher volumes of lower-margin seasonal products like FluMist and Beyfortus.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

Only 'one or two issues' remain unresolved in Iran-Oman talks, a senior diplomatic source tells Al Jazeera